Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.99 USD | -2.60% | -10.19% | -33.37% |
Financials (USD)
Sales 2024 * | 216M | Sales 2025 * | 304M | Capitalization | 456M |
---|---|---|---|---|---|
Net income 2024 * | -238M | Net income 2025 * | -163M | EV / Sales 2024 * | 2.66 x |
Net Debt 2024 * | 118M | Net Debt 2025 * | 69.33M | EV / Sales 2025 * | 1.73 x |
P/E ratio 2024 * |
-2.05
x | P/E ratio 2025 * |
-3.31
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -2.60% | ||
1 week | -10.19% | ||
Current month | -22.31% | ||
1 month | -20.03% | ||
3 months | -35.10% | ||
6 months | -17.95% | ||
Current year | -33.37% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 5.99 | -2.60% | 1,313,837 |
24-04-16 | 6.15 | -2.69% | 792,112 |
24-04-15 | 6.32 | -0.78% | 1,547,751 |
24-04-12 | 6.37 | -4.78% | 1,409,832 |
24-04-11 | 6.69 | +0.30% | 1,966,022 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.37% | 468M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- TVTX Stock